179 related articles for article (PubMed ID: 11914909)
1. Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer.
Rivera E; Valero V; Esteva FJ; Syrewicz L; Cristofanilli M; Rahman Z; Booser DJ; Hortobagyi GN
Cancer Chemother Pharmacol; 2002 Apr; 49(4):299-302. PubMed ID: 11914909
[TBL] [Abstract][Full Text] [Related]
2. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
Trudeau ME; Clemons MJ; Provencher L; Panasci L; Yelle L; Rayson D; Latreille J; Vandenberg T; Goel R; Zibdawi L; Rahim Y; Pouliot JF
J Clin Oncol; 2009 Dec; 27(35):5906-10. PubMed ID: 19858391
[TBL] [Abstract][Full Text] [Related]
3. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).
Coleman RE; Biganzoli L; Canney P; Dirix L; Mauriac L; Chollet P; Batter V; Ngalula-Kabanga E; Dittrich C; Piccart M
Eur J Cancer; 2006 May; 42(7):882-7. PubMed ID: 16520033
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen.
Warner E; Hedley D; Andrulis I; Myers R; Trudeau M; Warr D; Pritchard KI; Blackstein M; Goss PE; Franssen E; Roche K; Knight S; Webster S; Fraser RA; Oldfield S; Hill W; Kates R
Clin Cancer Res; 1998 Jun; 4(6):1451-7. PubMed ID: 9626462
[TBL] [Abstract][Full Text] [Related]
5. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer.
Giordano SH; Booser DJ; Murray JL; Ibrahim NK; Rahman ZU; Valero V; Theriault RL; Rosales MF; Rivera E; Frye D; Ewer M; Ordonez NG; Buzdar AU; Hortobagyi GN
Clin Cancer Res; 2002 Nov; 8(11):3360-8. PubMed ID: 12429622
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma.
Bramwell VH; Morris D; Ernst DS; Hings I; Blackstein M; Venner PM; Ette EI; Harding MW; Waxman A; Demetri GD
Clin Cancer Res; 2002 Feb; 8(2):383-93. PubMed ID: 11839653
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer.
Booser DJ; Esteva FJ; Rivera E; Valero V; Esparza-Guerra L; Priebe W; Hortobagyi GN
Cancer Chemother Pharmacol; 2002 Jul; 50(1):6-8. PubMed ID: 12111105
[TBL] [Abstract][Full Text] [Related]
8. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
Sutton G; Blessing J; Hanjani P; Kramer P;
Gynecol Oncol; 2005 Mar; 96(3):749-52. PubMed ID: 15721421
[TBL] [Abstract][Full Text] [Related]
9. A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline.
Hong RL; Lin CH; Chao TY; Kao WY; Wang CH; Hsieh RK; Hwang WS
Cancer Chemother Pharmacol; 2008 Apr; 61(5):847-53. PubMed ID: 17609947
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of anthracyclines and paclitaxel as first line chemotherapy in patients with visceral metastases of breast cancer.
Rossi D; Graziano F; Luzi Fedeli S; Fedeli A; Alessandroni P; Catalano V; Giordani P; Testa E; Catalano G
Minerva Med; 2002 Aug; 93(4):303-7. PubMed ID: 12207200
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of liposomal doxorubicin at 40 mg/m(2) every 4 weeks in endometrial carcinoma: a Gynecologic Oncology Group Study.
Homesley HD; Blessing JA; Sorosky J; Reid G; Look KY
Gynecol Oncol; 2005 Aug; 98(2):294-8. PubMed ID: 15975638
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
O'connor T; Rustum Y; Levine E; Creaven P
Cancer Chemother Pharmacol; 2008 Jan; 61(1):125-31. PubMed ID: 17426973
[TBL] [Abstract][Full Text] [Related]
13. Five-day infusion of fluorouracil and vinorelbine for advanced breast cancer patients treated previously with anthracyclines.
Pieńkowski T; Jagiello-Gruszfeld A
Int J Clin Pharmacol Res; 2001; 21(3-4):111-7. PubMed ID: 12067140
[TBL] [Abstract][Full Text] [Related]
14. Phase I-II trial of high-dose epirubicin in patients with lymphoma.
Case DC; Gams R; Ervin TJ; Boyd MA; Oldham FB
Cancer Res; 1987 Dec; 47(23):6393-6. PubMed ID: 3479245
[TBL] [Abstract][Full Text] [Related]
15. Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer.
Mlineritsch B; Schabel-Moser R; Andel J; Fridrik M; Moik M; Mayer P; Russ G; Rass C; Greil R;
Onkologie; 2009 Feb; 32(1-2):18-24. PubMed ID: 19209014
[TBL] [Abstract][Full Text] [Related]
16. Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study.
Ardavanis A; Mavroudis D; Kalbakis K; Malamos N; Syrigos K; Vamvakas L; Kotsakis A; Kentepozidis N; Kouroussis C; Agelaki S; Georgoulias V;
Cancer Chemother Pharmacol; 2006 Dec; 58(6):742-8. PubMed ID: 16718470
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of vinorelbine and pegylated liposomal doxorubicin in patients with pretreated metastatic breast cancer.
Chow LW; Yip AY; Lang BH
Am J Clin Oncol; 2007 Apr; 30(2):133-8. PubMed ID: 17414461
[TBL] [Abstract][Full Text] [Related]
18. Prediction of response to repeat utilization of anthracycline in recurrent breast cancer patients previously administered anthracycline-containing chemotherapeutic regimens as neoadjuvant or adjuvant chemotherapy.
Yonemori K; Katsumata N; Kaneko M; Uno H; Matsumoto K; Kouno T; Shimizu C; Ando M; Takeuchi M; Fujiwara Y
Breast Cancer Res Treat; 2007 Jul; 103(3):313-8. PubMed ID: 17063267
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of liposomal doxorubicin in advanced gynecologic cancers.
Israel VP; Garcia AA; Roman L; Muderspach L; Burnett A; Jeffers S; Muggia FM
Gynecol Oncol; 2000 Aug; 78(2):143-7. PubMed ID: 10926793
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of idarubicin given orally in the treatment of anthracycline-naive advanced breast cancer patients.
Bastholt L; Dalmark M
Cancer Treat Rep; 1987 May; 71(5):451-4. PubMed ID: 3471329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]